MDACC Study No:2013-0147 ( NCT No: NCT01856023)
Title:Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy«) in Patients with Metastatic Melanoma
Principal Investigator:Sapna P. Patel
Treatment Agent:HDIL-2; Ipilimumab
Study Status:Terminated
Study Description:The goal of this clinical research study is to compare if and how long 2
different study treatment plans with aldesleukin (also known as interleukin-2
or IL-2) and ipilimumab may be able to help control metastatic melanoma. The
safety of these treatment plans will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Melanoma
Phase of Study:Phase IV
Treatment Agents:HDIL-2
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Prometheus Laboratories Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Sapna P. Patel
Dept:Melanoma Medical Oncology
For Clinical Trial Enrollment:713-794-4274
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults